TippingPoint Biosciences has raised $4.5 million in an oversubscribed seed funding round to advance a novel drug discovery platform focused on previously “undruggable” epigenetic targets. The financing was led by SOSV and LKS Fund, with participation from Sazze Partners, Freeflow Ventures, StoryHouse Ventures, Sontag Innovation Fund, American Cancer Society BrightEdge, XEIA, and WeCAN.
The company is developing a new approach to precision medicine by targeting disease-specific epigenetic protein interfaces rather than conventional catalytic sites. Traditional epigenetic therapies have often struggled in clinical settings because they interfere with biological processes shared by both healthy and diseased cells. TippingPoint’s platform instead recreates disease-specific chromatin environments to uncover transient protein interactions unique to pathological states, enabling more selective drug targeting.
Founded by Laura Hsieh, PhD, and Geeta Narlikar, PhD, a chromatin biologist at the University of California, San Francisco, the company is rooted in research conducted in Narlikar’s lab. The platform aims to identify and exploit previously inaccessible targets within the epigenome by modeling the precise biological conditions under which disease-driving interactions occur.
TippingPoint plans to initially apply its technology to Diffuse Intrinsic Pontine Glioma, a highly aggressive pediatric brainstem tumor with limited treatment options. The disease is driven by disruptions in chromatin biology, making it a strong candidate for the company’s approach.
Prior to this seed round, the company raised $2.5 million in pre-seed funding, including non-dilutive grants, with support from organizations such as the Pediatric Brain Tumor Foundation and the Yuvaan Tiwari Foundation. It has also received multiple Golden Ticket awards from MBC BioLabs, AbbVie, Astellas, and ONO Pharmaceuticals.
The new funding will support advancement of the company’s lead program toward proof-of-concept studies in orthotopic DIPG models and further development of its epigenetic interface discovery platform. TippingPoint aims to expand the application of its technology beyond cancer into other diseases linked to chromatin dysfunction, including neurodegenerative and developmental disorders.
KEY QUOTE:
“Many of the most important interactions driving epigenetic disease only exist under very specific biological conditions. Our technologies precisely recreate those conditions, exposing actionable targets that are currently invisible to traditional drug discovery efforts.”
Laura Hsieh, PhD, Co-Founder And CEO, TippingPoint Biosciences
